Literature DB >> 32671985

Inherited variant in NFκB-1 promoter is associated with increased risk of IBD in an Algerian population and modulates SOX9 binding.

Imene Hamadou1, Sonia Garritano2, Alessandro Romanel2,3, Dalila Naimi4, Talel Hammada5, Francesca Demichelis2.   

Abstract

BACKGROUND: The link between inflammation and cancer development was intensively studied in the last decade. To date, few studies explored the association between inflammatory genes and colorectal cancer (CRC) development. AIM: The present study aimed to evaluate the implication of three single nucleotide polymorphisms (SNPs), rs28362491 ins/del -94 ATTG in NFκB1, rs6920220 (G/A) in TNFAIP3, and rs419598 (C/T) in IL1RN, which play a role in inflammation regulation in CRC development. METHODS AND
RESULTS: A case-control study was conducted on an Algerian cohort of 358 subjects (147 healthy people, 89 individuals affected by inflammatory bowel disease [IBD], and 122 CRC patients enrolled at the University Hospital Center Ben Badis of Constantine). SNPs genotyping was performed by allelic discrimination TaqMan assay. The rs28362491 ins/del heterozygous genotype in NFκB1 conferred an increased risk of IBD compared with ins/ins homozygous genotype, with an increase of twofold (OR = 2.34 [1.29-4.21]; 95% CI, 1.29-4.21, P value = 0.004). No significant association was detected for the other two variants. Dual-Luciferase Reporter Assay System performed in LoVo cells showed a significantly higher activity of the construct with ins allele of rs28362491 compared with the one harboring the del allele. Computational analysis nominated SOX9 as putative transcription factor (TF) with higher probability to bind the NFκB1 promoter at the SNP site, and we demonstrated in the in vitro assay that its overexpression modulates NFκB1 promoter activity in allele-specific manner.
CONCLUSION: We speculate that SOX9 may modulate the NFκB1 activity by binding its promoter at the SNP site in allelic specific manner.
© 2020 Wiley Periodicals, Inc.

Entities:  

Keywords:  NFκB; SNPs; colorectal cancer; inflammation

Year:  2020        PMID: 32671985      PMCID: PMC7941421          DOI: 10.1002/cnr2.1240

Source DB:  PubMed          Journal:  Cancer Rep (Hoboken)        ISSN: 2573-8348


  47 in total

1.  Interleukin-10 -592C/A, but not -1082A/G promoter single nucleotide polymorphism, is associated with a decreased risk of colorectal cancer in an ethnic Kashmiri population: a case-control study.

Authors:  Mujeeb Z Banday; Aga S Sameer; Nissar A Chowdri; Ehtishamul Haq
Journal:  Eur J Cancer Prev       Date:  2017-11       Impact factor: 2.497

2.  IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer.

Authors:  Florian R Greten; Lars Eckmann; Tim F Greten; Jin Mo Park; Zhi-Wei Li; Laurence J Egan; Martin F Kagnoff; Michael Karin
Journal:  Cell       Date:  2004-08-06       Impact factor: 41.582

Review 3.  Nuclear factor-kappaB activation: from bench to bedside.

Authors:  Gautam Sethi; Bokyung Sung; Bharat B Aggarwal
Journal:  Exp Biol Med (Maywood)       Date:  2008-01

4.  Inherited variant in NFκB-1 promoter is associated with increased risk of IBD in an Algerian population and modulates SOX9 binding.

Authors:  Imene Hamadou; Sonia Garritano; Alessandro Romanel; Dalila Naimi; Talel Hammada; Francesca Demichelis
Journal:  Cancer Rep (Hoboken)       Date:  2020-02-20

Review 5.  Evolving concepts of tumor heterogeneity.

Authors:  Victoria R Zellmer; Siyuan Zhang
Journal:  Cell Biosci       Date:  2014-11-25       Impact factor: 7.133

6.  Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease.

Authors:  Luke Jostins; Stephan Ripke; Rinse K Weersma; Richard H Duerr; Dermot P McGovern; Ken Y Hui; James C Lee; L Philip Schumm; Yashoda Sharma; Carl A Anderson; Jonah Essers; Mitja Mitrovic; Kaida Ning; Isabelle Cleynen; Emilie Theatre; Sarah L Spain; Soumya Raychaudhuri; Philippe Goyette; Zhi Wei; Clara Abraham; Jean-Paul Achkar; Tariq Ahmad; Leila Amininejad; Ashwin N Ananthakrishnan; Vibeke Andersen; Jane M Andrews; Leonard Baidoo; Tobias Balschun; Peter A Bampton; Alain Bitton; Gabrielle Boucher; Stephan Brand; Carsten Büning; Ariella Cohain; Sven Cichon; Mauro D'Amato; Dirk De Jong; Kathy L Devaney; Marla Dubinsky; Cathryn Edwards; David Ellinghaus; Lynnette R Ferguson; Denis Franchimont; Karin Fransen; Richard Gearry; Michel Georges; Christian Gieger; Jürgen Glas; Talin Haritunians; Ailsa Hart; Chris Hawkey; Matija Hedl; Xinli Hu; Tom H Karlsen; Limas Kupcinskas; Subra Kugathasan; Anna Latiano; Debby Laukens; Ian C Lawrance; Charlie W Lees; Edouard Louis; Gillian Mahy; John Mansfield; Angharad R Morgan; Craig Mowat; William Newman; Orazio Palmieri; Cyriel Y Ponsioen; Uros Potocnik; Natalie J Prescott; Miguel Regueiro; Jerome I Rotter; Richard K Russell; Jeremy D Sanderson; Miquel Sans; Jack Satsangi; Stefan Schreiber; Lisa A Simms; Jurgita Sventoraityte; Stephan R Targan; Kent D Taylor; Mark Tremelling; Hein W Verspaget; Martine De Vos; Cisca Wijmenga; David C Wilson; Juliane Winkelmann; Ramnik J Xavier; Sebastian Zeissig; Bin Zhang; Clarence K Zhang; Hongyu Zhao; Mark S Silverberg; Vito Annese; Hakon Hakonarson; Steven R Brant; Graham Radford-Smith; Christopher G Mathew; John D Rioux; Eric E Schadt; Mark J Daly; Andre Franke; Miles Parkes; Severine Vermeire; Jeffrey C Barrett; Judy H Cho
Journal:  Nature       Date:  2012-11-01       Impact factor: 49.962

7.  Polymorphisms in the inflammatory pathway genes TLR2, TLR4, TLR9, LY96, NFKBIA, NFKB1, TNFA, TNFRSF1A, IL6R, IL10, IL23R, PTPN22, and PPARG are associated with susceptibility of inflammatory bowel disease in a Danish cohort.

Authors:  Steffen Bank; Paal Skytt Andersen; Johan Burisch; Natalia Pedersen; Stine Roug; Julie Galsgaard; Stine Ydegaard Turino; Jacob Broder Brodersen; Shaista Rashid; Britt Kaiser Rasmussen; Sara Avlund; Thomas Bastholm Olesen; Hans Jürgen Hoffmann; Marianne Kragh Thomsen; Vibeke Ostergaard Thomsen; Morten Frydenberg; Bjørn Andersen Nexø; Jacob Sode; Ulla Vogel; Vibeke Andersen
Journal:  PLoS One       Date:  2014-06-27       Impact factor: 3.240

8.  SOX9-regulated cell plasticity in colorectal metastasis is attenuated by rapamycin.

Authors:  Estefania Carrasco-Garcia; Lidia Lopez; Paula Aldaz; Sara Arevalo; Juncal Aldaregia; Larraitz Egaña; Luis Bujanda; Martin Cheung; Nicolas Sampron; Idoia Garcia; Ander Matheu
Journal:  Sci Rep       Date:  2016-08-30       Impact factor: 4.379

9.  SOX9 is an atypical intestinal tumor suppressor controlling the oncogenic Wnt/ß-catenin signaling.

Authors:  Corinne Prévostel; Cyrine Rammah-Bouazza; Hélène Trauchessec; Lucile Canterel-Thouennon; Muriel Busson; Marc Ychou; Philippe Blache
Journal:  Oncotarget       Date:  2016-12-13

10.  Combined effects of three independent SNPs greatly increase the risk estimate for RA at 6q23.

Authors:  Gisela Orozco; Anne Hinks; Steve Eyre; Xiayi Ke; Laura J Gibbons; John Bowes; Edward Flynn; Paul Martin; Anthony G Wilson; Deborah E Bax; Ann W Morgan; Paul Emery; Sophia Steer; Lynne Hocking; David M Reid; Paul Wordsworth; Pille Harrison; Wendy Thomson; Anne Barton; Jane Worthington
Journal:  Hum Mol Genet       Date:  2009-05-05       Impact factor: 6.150

View more
  3 in total

1.  Inherited variant in NFκB-1 promoter is associated with increased risk of IBD in an Algerian population and modulates SOX9 binding.

Authors:  Imene Hamadou; Sonia Garritano; Alessandro Romanel; Dalila Naimi; Talel Hammada; Francesca Demichelis
Journal:  Cancer Rep (Hoboken)       Date:  2020-02-20

2.  Contributions of NFKB1 -94insertion/deletion ATTG polymorphism to the susceptibility of gastrointestinal cancers: A meta-analysis.

Authors:  Hanqiang Wu; Jianrong Liang
Journal:  J Cell Mol Med       Date:  2021-10-21       Impact factor: 5.310

3.  The landscape of GWAS validation; systematic review identifying 309 validated non-coding variants across 130 human diseases.

Authors:  Ammar J Alsheikh; Sabrina Wollenhaupt; Emily A King; Jonas Reeb; Sujana Ghosh; Lindsay R Stolzenburg; Saleh Tamim; Jozef Lazar; J Wade Davis; Howard J Jacob
Journal:  BMC Med Genomics       Date:  2022-04-01       Impact factor: 3.063

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.